Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | FHIT | P49789 | 2/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444064 | 0.87 | POLB (0.44) | ADH1AFHIT | |
| SCHEMBL20691954 | 0.80 | NT5E (0.51) | NT5EFHIT | |
| SCHEMBL24258564 | 0.79 | IMPDH2 (0.46) | IMPDH2NT5EADH1AFHITIMPDH1 | |
| SCHEMBL24444116 | 0.78 | POLB (0.46) | ADH1A | |
| SCHEMBL22080505 | 0.77 | NT5E (0.53) | NT5EFHIT | |
| SCHEMBL22080123 | 0.76 | NT5E (0.51) | NT5EFHIT | |
| SCHEMBL22080564 | 0.76 | NT5E (0.51) | NT5EFHIT | |
| SCHEMBL18822973 | 0.76 | NT5E (0.51) | NT5EFHIT | |
| SCHEMBL22858409 | 0.76 | IMPDH2 (0.53) | IMPDH2ADH1AIMPDH1 | |
| SCHEMBL23476718 | 0.75 | NT5E (0.55) | NT5EFHIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | IMPDH2 84/4885NT5E 102/4885ADH1A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.